The Cell and Gene therapy market has a projected CAGR of more than 35% over the next decade. Today four therapies have been approved but with a current pipeline of 900 new products, by 2025, the FDA expects up to 20 approvals a year.
CGT supply chains differ from the conventional supply chain in many ways. With bluecrux, we are actively collaborating with leading CGT manufacturers. Time for us to share our findings and vision. Time for you to get inspired & take some action for your own business!